One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Affimed N.V. logo
Affimed N.V. AFMD
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Affimed N.V. Cash Flow 2023-2011 | AFMD

Brief overview of Affimed N.V.'s cash generation

Cash flows are assessed across five available annual periods spanning 2019 to 2023.

Operating cash flow ended negative at -€110.3 million. Core operations are not yet producing a sustainable inflow.

Operating cash flow was positive in only 0 of five periods. Cash generation remains unstable.

Overall picture

Taken together, Affimed N.V.'s cash flow indicators point to increased dependence on reserves or outside financing.

Annual Cash Flow Affimed N.V.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-110 M -105 M -86.6 M -19.4 M -29.1 M 49.4 M -25.5 M -32.1 M -18.5 M - - - -

All numbers in EUR currency

Quarterly Cash Flow Affimed N.V.

2024-Q2 2023-Q4 2023-Q3 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-40.3 M -110 M - -66.6 M - - -54.9 M - -86.6 M - -33.4 M - -19.4 M - -31.5 M - -29.1 M - -18.9 M - 49.4 M - -15.2 M - -25.5 M - - - -32.1 M - - - -18.5 M - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Cash Flow Statement is one of the three key financial reports of the company Affimed N.V., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 0.62 1.33 % $ 66.1 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Seer Seer
SEER
$ 1.61 -0.31 % $ 88.9 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Shattuck Labs Shattuck Labs
STTK
$ 5.04 3.61 % $ 351 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 19.78 -0.05 % $ 2.8 B britainBritain
Stoke Therapeutics Stoke Therapeutics
STOK
$ 27.75 1.98 % $ 1.64 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 10.25 0.79 % $ 87.1 M usaUSA
Soligenix Soligenix
SNGX
$ 0.32 0.37 % $ 1.66 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 43.19 1.85 % $ 49.5 B israelIsrael
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.96 2.78 % $ 2.01 M chinaChina
Spruce Biosciences Spruce Biosciences
SPRB
$ 46.52 -0.32 % $ 35.7 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 20.83 -0.38 % $ 32.9 B japanJapan
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 29.29 1.88 % $ 1.65 B usaUSA
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Savara Savara
SVRA
$ 5.03 2.24 % $ 1.12 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
$ 65.76 2.33 % $ 9.49 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 14.83 -0.57 % $ 2 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
$ 977.91 0.65 % $ 59.9 B niderlandNiderland
XBiotech XBiotech
XBIT
$ 1.95 -1.02 % $ 59.5 M usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.87 3.68 % $ 3.18 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 31.22 1.17 % $ 3.18 B usaUSA